Mostrando 6 resultados de: 6
Filtros aplicados
Publisher
Biomedicine and Pharmacotherapy(1)
Cell and Bioscience(1)
Expert Opinion on Drug Discovery(1)
Journal of Alzheimer's Disease(1)
Neural Plasticity(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(5)
ODS 3: Salud y bienestar(5)
ODS 2: Hambre cero(2)
ODS 4: Educación de calidad(1)
ODS 8: Trabajo decente y crecimiento económico(1)
Origen
scopus(6)
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusMemantine for the treatment of dementia: A review on its current and future applications
ReviewAbstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brainPalabras claves:Alzheimer's disease, Amyloid-protein, Extrasynaptic N-Methyl-D-aspartate receptor, Memantine, Tau proteinAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Olloquequi J., Pelegrí Gabalda C., Sanchez-Lopez E., Verdaguer E., Vilaplana J., Zárate C.B.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusProtein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
ReviewAbstract: Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct nPalabras claves:Alzheimer's disease, insulin receptor, neurodegenerative diseases, neuroinflammation, Neurological disorders, PTP1B, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Cano A., Carrasco M., Ettcheto M., Folch J., Fortuna A., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus